X
1. 220352-38-5
2. 1006614-49-8
3. (1r,2s)-2-(3,4-difluorophenyl)cyclopropan-1-amine
4. Cyclopropanamine, 2-(3,4-difluorophenyl)-, (1r,2s)-
5. (1r,2s)-rel-2-(3,4-difluorophenyl)cyclopropanamine
6. (1r,2s)-2-(3,4-difluoro-phenyl)-cyclopropylamine
7. Oiy4b72tg1
8. (1r, 2s)-rel-2-(3, 4-difluorophenyl)cyclopropanamine
9. (1r,2s)-2-(3,4-difluorophenyl)cyclopropylamine
10. 2-(3,4-difluorophenyl)cyclopropanamine, (1r,2s)-
11. Cyclopropanamine, 2-(3,4-difluorophenyl)-, (1r,2s)-rel-
12. Unii-oiy4b72tg1
13. Schembl245340
14. Ambz0380
15. Ticagrelor Related Compound 31
16. Chembl4589166
17. Dtxsid70431443
18. Mfcd16621156
19. Zinc33975233
20. Akos015951193
21. Ac-25874
22. Am20090745
23. Cs-0006751
24. A850997
25. (1r-trans)-2-(3,4-difluorophenyl)cyclopropanamine
26. (1r,2s)-2-(3,4-difluorophenyl)cyclopropane-1-amine
27. Cyclopropanamine,2-(3,4-difluorophenyl)-,(1r,2s)-
28. F1916-7272
29. (1r Trans)-2-(3,4-difluorophenyl)cyclopropane Amine
30. Trans-(1r,2s)-2-(3,4-difluorophenyl)cyclopropylamine
| Molecular Weight | 169.17 g/mol |
|---|---|
| Molecular Formula | C9H9F2N |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 169.07030562 g/mol |
| Monoisotopic Mass | 169.07030562 g/mol |
| Topological Polar Surface Area | 26 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 174 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
List of SuppliersNote: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
RDD 2024
Not Confirmed
Contact Supplier
Market Place
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
